COVID-19 Therapeutics – Product Information

This page contains product-specific information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.

Bebtelovimab (Lilly)

• Emergency Use Authorization (EUA) for emergency use of bebtelovimab
• Bebtelovimab Fact Sheet for U.S. Health Care Providers (English)
• FDA Frequently Asked Questions on the Emergency Use Authorization of Bebtelovimab
• Bebtelovimab Fact Sheet for Patients and Caregivers (English)
• Bebtelovimab Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
• Bebtelovimab shelf-life extended (ASPR)

Bamlanivimab and Etesevimab (Lilly)

• Shelf-Life Extension for Bamlanivimab (ASPR)
• Shelf-Life Extension of Bamlanivimab and Etesevimab
• Emergency Use Authorization (EUA) for emergency use of bamlanivimab and etesevimab
• Bamlanivimab and Etesevimab Fact Sheet for Healthcare Providers
• FDA Frequently Asked Questions on the Emergency Use Authorization for Bamlanivimab and Etesevimab
• Dear HCP Letter: Bamlanivimab and Etesevimab, Preventing Medication Errors
• Bamlanivimab and Etesevimab Fact Sheet for Patients, Parents and Caregivers (English)
• Bamlanivimab and Etesevimab Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores: Autorización de uso de emergencia (EUA) de bamlanivimab y etesevimab para la enfermedad por coronavirus 2019 (COVID-19)
• Lilly bamlanivimab and etesevimab information
• Lilly Bamlanivimab and Etesevimab Together Antibody Playbook

Note: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab when given alone

Casirivimab/Imdevimab (Regeneron)

• Shelf-Life Extension for REGEN-COV (ASPR)
• Emergency Use Authorization (EUA) for emergency use of casirivimab and imdevimab
• FDA Frequently Asked Questions on the Emergency Use Authorization of Casirivimab + Imdevimab
• Casirivimab/Imdevimab Fact Sheet for U.S. Health Care Providers (English)
• REGEN-COV: Subcutaneous Injection Instructions for Healthcare Providers
• Important Prescribing Information: A Letter from Regeneron to Healthcare Providers on Preventing Medication Errors
• REGEN-COV Packaging Overview
• REGEN-COV (casirivimab and imdevimab) Fact Sheet for Patients and Caregivers (English)
• REGEN-COV (casirivimab and imdevimab) Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
• Regeneron casirivimab/imdevimab information
• Regeneron casirivimab/imdevimab guidebook
• Overview, Allocation & Distribution (casirivimab/imdevimab)

Sotrovimab (GlaxoSmithKline)

• Shelf-Life Extension for Sotrovimab (ASPR)
• Sotrovimab Fact Sheet for U.S. Health Care Providers (English)
• Emergency Use Authorization (EUA) for emergency use of sotrovimab
• FDA Frequently Asked Questions on the Emergency Use Authorization of Sotrovimab
• Sotrovimab Fact Sheet for Patients and Caregivers (English)
• Sotrovimab Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
• GlaxoSmithKline sotrovimab information
• A Detailed Guide for the Use of Sotrovimab
• Access & Reimbursement Information for Sotrovimab

Evusheld (tixagevimab co-packaged with cilgavimab) (AstraZeneca)

• Shelf-Life Extension for Evusheld (ASPR)
• Emergency Use Authorization (EUA) for emergency use of Evusheld
• Evusheld Fact Sheet for Healthcare Providers
• NIH Statement on Evusheld for Pre-Exposure Prophylaxis
• Frequently Asked Questions on the Emergency Use Authorization for Evusheld
• Evusheld Fact Sheet for Patients, Parents, and Caregivers (English)
• Evusheld Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
• AstraZeneca Evusheld information
• AstraZeneca Evusheld Coding Resource
• US HHS ASPR Frequently Asked Questions

Lagevrio (molnupiravir) (Merck)

• Emergency Use Authorization (EUA) for emergency use of Lagevrio
• Lagevrio Fact Sheet for Healthcare Providers (English)
• Hoja de Datos para Proveedores de atención médica para Lagevrio
• Frequently Asked Questions on the Emergency Use Authorization for Lagevrio
• Healthcare Provider Letter: Important Safety Information Regarding Use of Lagevrio in Pregnancy and Individuals of Childbearing Potential
• Prescriber Checklist for Lagevrio
• Lagevrio Fact Sheet for Patients, Parents, and Caregivers (English)
• Lagevrio Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
• US HHS ASPR Frequently Asked Questions

Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) (Pfizer)

• Emergency Use Authorization (EUA) for emergency use of Paxlovid
• Paxlovid Fact Sheet for Healthcare Providers (English)
• PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers (FDA)
• Frequently Asked Questions on the Emergency Use Authorization for Paxlovid
• NIH Statement on Paxlovid Drug-Drug Interactions
• Healthcare Provider Letter: PAXLOVID EUA dosing and dispensing in moderate renal impairment, and risk of serious adverse reactions due to drug interactions
• COVID-19 Drug Interactions Checker (University of Liverpool) – (app available)
• Paxlovid Drug Interaction Checker
• Management of Drug Interactions With Paxlovid: Resource for Clinicians (The Infectious Diseases Society of America)
• Instructions for Pharmacists for Paxlovid (Pfizer)
• Important Dispensing Information for Patients with Moderate Renal Impairment
• Paxlovid Fact Sheet for Patients, Parents, and Caregivers (English)
• Paxlovid Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
• Q&A with FDA Director of the Office of Infectious Diseases about Paxlovid Updates (FDA)
• Shelf-Life Extension for Paxlovid from 9 to 12 months and Shelf-Life Extension for Paxlovid from 12 to 19 months
• US HHS ASPR Frequently Asked Questions

▲ Top